Long-term treatment with Tyvaso DPI safely and effectively leads to increases in exercise capacity in adults with pulmonary arterial…
Articles by Lila Levinson, PhD
Underweight infants with pulmonary hypertension (PH) are at increased risk of developing retinopathy of prematurity (ROP), a leading cause…
Corvista Health’s point-of-care device can detect cases of pulmonary hypertension (PH) that other noninvasive diagnostic tools miss, according…
Cereno Scientific has received fast track designation from the U.S. Food and Drug Administration (FDA) for CS1, its therapy…
Most people with pulmonary arterial hypertension (PAH) are not referred for a lung transplant, despite clinical recommendations that referral…
Providing a protein called BMPER that is found at low levels in models of pulmonary arterial hypertension (PAH) may ease disease…
The U.S. Food and Drug Administration (FDA) has accepted Gradient Denervation Technologies, a company that makes an ultrasound-based catheter…
A Phase 2b clinical trial of Insmed’s treprostinil palmitil inhalation powder (TPIP) suggested daily doses of the inhaled dry…
A Phase 2a study of HB-1614, an oral therapy candidate, suggested the medication is safe and may improve exercise capacity…